M&A Deal Summary

AMAG Pharmaceuticals Acquires Perosphere Pharmaceuticals

On December 13, 2018, AMAG Pharmaceuticals acquired life science company Perosphere Pharmaceuticals

Acquisition Highlights
  • This is AMAG Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is AMAG Pharmaceuticals’ 3rd transaction in the United States.
  • This is AMAG Pharmaceuticals’ 1st transaction in Connecticut.

M&A Deal Summary
Date 2018-12-13
Target Perosphere Pharmaceuticals
Sector Life Science
Buyer(s) AMAG Pharmaceuticals
Deal Type Add-on Acquisition

Target

Perosphere Pharmaceuticals

Danbury, Connecticut, United States
Perosphere Pharmaceuticals, Inc. is a private clinical-stage company focused on developing rescue drugs. Perosphere Pharma's lead investigational drug product candidate, ciraparantag (PER977), is an FDA Fast Track designated, intravenously administered small synthetic water-soluble new molecular entity intended for use as a reversal agent for the orally administered direct Factor Xa inhibitors and low molecular weight heparin.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AMAG Pharmaceuticals

Waltham, Massachusetts, United States
Category Company
Founded 1981
Sector Life Science
Employees440
Revenue 328M USD (2019)
DESCRIPTION

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse. AMAG Pharmaceuticals was formed in 1981 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 3 of 3
State (Connecticut) 1 of 1
Country (United States) 3 of 3
Year (2018) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-17 Cord Blood Registry

San Bruno, California, United States

CBR Systems is a late-stage medical devices company with the leading market position in providing the collection, processing and cryogenically-frozen storage of stem cells.

Buy $700M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-21 AMAG Pharmaceuticals - INTRAROSA Rights

Waltham, Massachusetts, United States

INTRAROSA is a vaginal non-estrogen treatment for moderate to severe painful sex due to menopause. It is made with a plant-derived form of DHEA combined with coconut and palm oils.

Sell $125M
Mergr

Product

Company

Legal